Molecular subtypes of glioblastoma are relevant to lower grade glioma

PLoS ONE

Volumn 9, Issue 3, 2014, Pages

  Guan, Xiaowei ^a   Vengoechea, Jaime ^a,b   Zheng, Siyuan ^c   Sloan, Andrew E ^a,b   Chen, Yanwen ^a   Brat, Daniel J ^d   O'Neill, Brian Patrick ^e   De Groot, John ^c   Yust Katz, Shlomit ^c   Yung, Wai Kwan Alfred ^c   Cohen, Mark L ^a,b   Aldape, Kenneth D ^c   Rosenfeld, Steven ^f   Verhaak, Roeland G W ^c   Barnholtz Sloan, Jill S ^a  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^c UNIVERSITY OF TEXAS   (United States)

^d EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e MAYO CLINIC   (United States)

^f LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 2A; EPIDERMAL GROWTH FACTOR RECEPTOR; ISOCITRATE DEHYDROGENASE 1; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; ISOCITRATE DEHYDROGENASE;

ADULT; ARTICLE; CANCER GRADING; CDKN2A GENE; COPY NUMBER VARIATION; DISEASE COURSE; DNA METHYLATION; EGFR GENE; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE MUTATION; GENETIC ASSOCIATION; GENETIC PREDISPOSITION; GLIOBLASTOMA; GLIOMA; GLIOMA CPG ISLAND METHYLATOR PHENOTYPE; HUMAN; HUMAN TISSUE; IDH1 GENE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; OVERALL SURVIVAL; PHENOTYPE; PREDICTION; PTEN GENE; SINGLE NUCLEOTIDE POLYMORPHISM; BRAIN TUMOR; CLASSIFICATION; CPG ISLAND; FEMALE; GENE EXPRESSION REGULATION; GENETICS; MUTATION; PATHOLOGY; SURVIVAL ANALYSIS;

BRAIN NEOPLASMS; CPG ISLANDS; DNA COPY NUMBER VARIATIONS; DNA METHYLATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GLIOBLASTOMA; GLIOMA; HUMANS; ISOCITRATE DEHYDROGENASE; MALE; MIDDLE AGED; MUTATION; NEOPLASM GRADING; SURVIVAL ANALYSIS;

EID: 84897475322     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0091216     Document Type: Article

References (34)

1. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, et al. (2007) The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 114: 97-109. (Pubitemid 47103521)
2. Brennan CW, Verhaak RG, Mckenna A, Campos B, Noushmehr H, et al. (2013) Somatic genomic landscape of glioblastoma. submitted to cell.
3. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, et al. (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352: 987-996. (Pubitemid 40349501)
4. Cavaliere R, Lopes MB, Schiff D (2005) Low-grade gliomas: an update on pathology and therapy. Lancet Neurol 4: 760-770. (Pubitemid 41457292)
5. Schomas DA, Laack NN, Rao RD, Meyer FB, Shaw EG, et al. (2009) Intracranial low-grade gliomas in adults: 30-year experience with long-term follow-up at Mayo Clinic. Neuro Oncol 11: 437-445.
6. Lin CL, Lieu AS, Lee KS, Yang YH, Kuo TH, et al. (2003) The conditional probabilities of survival in patients with anaplastic astrocytoma or glioblastoma multiforme. Surg Neurol 60: 402-406; discussion 406.
7. van den Bent MJ (2010) Interobserver variation of the histopathological diagnosis in clinical trials on glioma: a clinician's perspective. Acta Neuropathol 120: 297-304.
8. Coons SW, Johnson PC, Scheithauer BW, Yates AJ, Pearl DK (1997) Improving diagnostic accuracy and interobserver concordance in the classification and grading of primary gliomas. Cancer 79: 1381-1393. (Pubitemid 27143246)
9. Giannini C, Scheithauer BW, Weaver AL, Burger PC, Kros JM, et al. (2001) Oligodendrogliomas: reproducibility and prognostic value of histologic diagnosis and grading. J Neuropathol Exp Neurol 60: 248-262. (Pubitemid 32209644)
10. Li A, Walling J, Ahn S, Kotliarov Y, Su Q, et al. (2009) Unsupervised analysis of transcriptomic profiles reveals six glioma subtypes. Cancer Res 69: 2091-2099.
11. Verhaak RG, Hoadley KA, Purdom E, Wang V, Qi Y, et al. (2010) Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 17: 98-110.
12. Phillips HS, Kharbanda S, Chen R, Forrest WF, Soriano RH, et al. (2006) Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell 9: 157-173. (Pubitemid 43357943)
13. Noushmehr H, Weisenberger DJ, Diefes K, Phillips HS, Pujara K, et al. (2010) Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell 17: 510-522.
14. TCGA (2008) Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 455: 1061-1068.
15. Turcan S, Rohle D, Goenka A, Walsh LA, Fang F, et al. (2012) IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype. Nature 483: 479-483.
16. Lu C, Ward PS, Kapoor GS, Rohle D, Turcan S, et al. (2012) IDH mutation impairs histone demethylation and results in a block to cell differentiation. Nature 483: 474-478.
17. Dang L, White DW, Gross S, Bennett BD, Bittinger MA, et al. (2009) Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature 462: 739-744.
18. Parsons DW, Jones S, Zhang X, Lin JC, Leary RJ, et al. (2008) An integrated genomic analysis of human glioblastoma multiforme. Science 321: 1807-1812.
19. Yan H, Parsons DW, Jin G, McLendon R, Rasheed BA, et al. (2009) IDH1 and IDH2 mutations in gliomas. N Engl J Med 360: 765-773.
20. Dubbink HJ, Taal W, van Marion R, Kros JM, van Heuvel I, et al. (2009) IDH1 mutations in low-grade astrocytomas predict survival but not response to temozolomide. Neurology 73: 1792-1795.
21. Houillier C, Wang X, Kaloshi G, Mokhtari K, Guillevin R, et al. (2010) IDH1 or IDH2 mutations predict longer survival and response to temozolomide in low-grade gliomas. Neurology 75: 1560-1566.
22. Iwamoto FM, Nicolardi L, Demopoulos A, Barbashina V, Salazar P, et al. (2008) Clinical relevance of 1p and 19q deletion for patients with WHO grade 2 and 3 gliomas. J Neurooncol 88: 293-298.
23. Dunning MJ, Smith ML, Ritchie ME, Tavare S (2007) beadarray: R classes and methods for Illumina bead-based data. Bioinformatics 23: 2183-2184. (Pubitemid 47394121)
24. Lai A, Kharbanda S, Pope WB, Tran A, Solis OE, et al. (2011) Evidence for sequenced molecular evolution of IDH1 mutant glioblastoma from a distinct cell of origin. J Clin Oncol 29: 4482-4490.
25. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, et al. (2005) Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A 102: 15545-15550. (Pubitemid 41528093)
26. Barbie DA, Tamayo P, Boehm JS, Kim SY, Moody SE, et al. (2009) Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1. Nature 462: 108-112.
27. Baysan M, Bozdag S, Cam MC, Kotliarova S, Ahn S, et al. (2012) G-cimp status prediction of glioblastoma samples using mRNA expression data. PLoS One 7: e47839.
28. Beroukhim R, Getz G, Nghiemphu L, Barretina J, Hsueh T, et al. (2007) Assessing the significance of chromosomal aberrations in cancer: methodology and application to glioma. Proc Natl Acad Sci U S A 104: 20007-20012.
29. Reich M, Liefeld T, Gould J, Lerner J, Tamayo P, et al. (2006) GenePattern 2.0. Nat Genet 38: 500-501.
30. Noushmehr H, Weisenberger DJ, Diefes K, Phillips HS, Pujara K, et al. Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell 17: 510-522.
31. Cooper LA, Gutman DA, Long Q, Johnson BA, Cholleti SR, et al. (2010) The proneural molecular signature is enriched in oligodendrogliomas and predicts improved survival among diffuse gliomas. PLoS One 5: e12548.
32. Lang FF, Miller DC, Koslow M, Newcomb EW (1994) Pathways leading to glioblastoma multiforme: a molecular analysis of genetic alterations in 65 astrocytic tumors. J Neurosurg 81: 427-436. (Pubitemid 24267651)
33. Yip S, Butterfield YS, Morozova O, Chittaranjan S, Blough MD, et al. (2012) Concurrent CIC mutations, IDH mutations, and 1p/19q loss distinguish oligodendrogliomas from other cancers. J Pathol 226: 7-16.
34. Jiao Y, Killela PJ, Reitman ZJ, Rasheed AB, Heaphy CM, et al. (2012) Frequent ATRX, CIC, FUBP1 and IDH1 mutations refine the classification of malignant gliomas. Oncotarget 3: 709-722.